Nivolumab Provides Long-term Benefit after Auto-HCT Classical Hodgkin Lymphoma

Share this content:
An interim analysis of a cohort in the CheckMate-205 study showed that nivolumab had an acceptable safety profile and demonstrated efficacy among patients with relapsed and refractory classical Hodgki
An interim analysis of a cohort in the CheckMate-205 study showed that nivolumab had an acceptable safety profile and demonstrated efficacy among patients with relapsed and refractory classical Hodgki
The following article features coverage from the Chemotherapy Foundation Symposium (CFS) in New York, NY. Click here to read more of Cancer Therapy Advisor's conference coverage.

Nivolumab may provide long-term clinical benefits for patients with relapsed/refractory (R/R) classical Hodgkin Lymphoma (cHL) after autologous hematopoietic cell transplantation (auto-HCT), according to a poster presented at the 35th Annual Chemotherapy Foundation Symposium in New York.1

An interim analysis of a cohort in the CheckMate-205 study showed that nivolumab had an acceptable safety profile and demonstrated efficacy among patients with R/R cHL after post-auto-HCT brentuximab vedotin (BV).

For this extended analysis of the CheckMate-205 study, researchers administered intravenous nivolumab to 243 patients with R/R cHL who were separated into 3 cohorts: patients who were BV naive (cohort A), patients who had BV after auto-HCT (cohort B), and patients who had BV before and/or after auto-HCT (cohort C).

More than 95% of evaluable study patients had reduced tumor burden at time of analysis.

The overall response rate (ORR) was 69%, with 33% and 39% of patients achieving complete response (CR) and partial response, respectively.

The overall median progression-free survival (PFS) was 15 months; median PFS in cohort A was 18 months (95% CI, 11-22), cohort B was 15 months (95% CI, 11-20), and cohort C was 12 months (95% CI, 11-18).

The overall median duration of response was 17 months, and lasted at least 15 months in all cohorts. Median overall survival (OS) was not reached in any cohort.

A post-hoc analysis revealed that patients refractory to first-line therapy, most recent prior line of therapy, and BV after auto-HCT achieved ORRs of 73%, 68%, and 68%, respectively, with 18%, 13%, and 7% achieving CRs, respectively.

Specifically, patients in cohort B had an ORR of 70% (95% CI, 51-84), and patients in cohort C had an ORR of 71% (95% CI, 63-78).

The median duration of response among patients refractory to first-line therapy, most recent prior line of therapy, and BV after auto-HCT was 17 months (95% CI, 13-not evaluable), 17 months (95% CI, 13-not evaluable), and 17 months (95% CI, 9-not evaluable), respectively.

Of the 44 nivolumab-treated patients who received allo-HCT, the incidence of transplant-related mortality (TRM) and GVHD post-allo-HCT were similar to historical data in cHL post-allo-HCT. Earlier literature had reported 100-day incidences of 26% to 60% for grade 2 to 4 acute GVHD and 6% to 28% for TRM.

Regarding safety, 23% of the study population experienced drug-related grade 3 to 4 adverse events; no treatment-related deaths were reported.

Editor's Note: This article was corrected to reflect the study name, which is CheckMate-205.

Read more of Cancer Therapy Advisor's coverage of the Chemotherapy Foundation Symposium (CFS) by visiting the conference page.

Reference

  1. Fanale M, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classical Hodgkin Lymphoma after autologous transplant: full results after extended follow-up of the phase 2 CheckMate 205 trial. Poster presented at: 35th Annual Chemotherapy Foundation Symposium; New York; November 8-10, 2017. Poster 561.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs